Company Filing History:
Years Active: 2013-2015
Title: Shirley Sameach-Greenwald: Innovator in Therapeutics and Drug Development
Introduction
Shirley Sameach-Greenwald is a prominent inventor based in Kfar-Saba, Israel. She has made significant contributions to the field of therapeutics and drug development, holding two patents that focus on innovative approaches to cancer treatment and disease diagnosis.
Latest Patents
Her latest patents involve polypeptides and polynucleotides, which serve as drug targets for producing drugs and biologics. This invention relates to a novel target for the production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32, or FXYD3 antigens, which are predicted co-stimulatory family members and are differentially expressed in cancers, including lung cancer, ovarian cancer, and colon cancer. The use of these antibodies for modulating B7 costimulation and related therapies, such as the treatment of autoimmunity, is also provided. Furthermore, this invention relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants, which are suitable targets for immunotherapy, cancer therapy, and drug development.
Career Highlights
Shirley is currently associated with Compugen Ltd. Corporation, where she continues to advance her research and innovations in the field of biotechnology. Her work has the potential to significantly impact therapeutic strategies for various cancers and autoimmune diseases.
Collaborations
Some of her notable coworkers include Amir Toporik and Amit Novik, who collaborate with her on various projects within the company.
Conclusion
Shirley Sameach-Greenwald is a trailblazer in the field of therapeutics, with her innovative patents paving the way for new treatments in cancer and autoimmune diseases. Her contributions are vital to the ongoing advancements in drug development and immunotherapy.